



SAFETY DATA SHEET

Revision date: 29-May-2018

Version: 4.1

Page 1 of 13

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Exemestane Tablets

Trade Name: Aromasin; Aromasine; Exemestane Pfizer

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B

Acute aquatic toxicity: Category 2

Chronic aquatic toxicity: Category 2

Label Elements

Signal Word: Danger

Hazard Statements: H360FD - May damage fertility. May damage the unborn child.

H411 - Toxic to aquatic life with long lasting effects

Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 2 of 13
Version: 4.1



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Exemestane	107868-30-4	Not Listed	Repr.1B (H360FD) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)	25
Silica colloidal, Ph. Eur.	112945-52-5	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Crospovidone	9003-39-8	Not Listed	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*
Mannitol	69-65-8	200-711-8	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Macrogol 6000	Not assigned	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*
Polyvinyl alcohol	9002-89-5	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	*
Simethicone emulsion	67762-90-7	Not Listed	Not Listed	*
Magnesium carbonate	39409-82-0	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 3 of 13
Version: 4.1

4. FIRST AID MEASURES

Description of First Aid Measures

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Medical Conditions Aggravated by Exposure:** None known

Indication of the Immediate Medical Attention and Special Treatment Needed

- Notes to Physician:** None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

- Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.
- Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

- Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
- Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 4 of 13
Version: 4.1

7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Exemestane

Pfizer OEL TWA-8 Hr: 8 µg/m³

Silica colloidal, Ph. Eur.

Austria OEL - MAKs 4 mg/m³
Germany (DFG) - MAK 4 mg/m³
Switzerland OEL -TWAs 4 mg/m³

Magnesium stearate

Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³
Latvia OEL - TWA 2 mg/m³
OSHA - Final PELs - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Romania OEL - TWA 10 mg/m³
Russia OEL - TWA 6 mg/m³
Spain OEL - TWA 10 mg/m³
Switzerland OEL -TWAs 3 mg/m³
Vietnam OEL - TWAs 10 mg/m³
5 mg/m³

Sucrose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 5 of 13
Version: 4.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	5 mg/m ³
	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	6 mg/m ³
	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 6 of 13
Version: 4.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	Off-white to gray
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Exemestane

Measured 7 Log P 2.5

Silica colloidal, Ph. Eur.

No data available

Crospovidone

No data available

Magnesium carbonate

No data available

Magnesium stearate

No data available

Mannitol

No data available

Microcrystalline cellulose

No data available

Methylparaben

No data available

Macrogol 6000

No data available

Polysorbate 80

No data available

Polyvinyl alcohol

No data available

Sodium starch glycolate

No data available

Sucrose

No data available

Simethicone emulsion

No data available

Hydroxypropyl methylcellulose

No data available

Titanium dioxide

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 7 of 13
Version: 4.1

Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: There are no data for this formulation. The remaining information describes the potential hazards of the individual ingredients.
Short Term: May cause minimal eye irritation (based on animal data). Active ingredient is not a skin irritant . Active ingredient is not a skin sensitizer . Not acutely toxic (based on animal data) .
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system.
Known Clinical Effects: Adverse effects associated with therapeutic use include hot flashes, nausea, fatigue, increased sweating, increased appetite, asthenia, and fever.

Acute Toxicity: (Species, Route, End Point, Dose)

Exemestane

Rat Oral LD 50 > 5000 mg/kg
Mouse Oral LD 50 > 3000mg/kg
Rat Intraperitoneal LD 50 404-488mg/kg
Mouse Intraperitoneal LD 50 396-419mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Mannitol

Rat Oral LD 50 13500 mg/kg
Mouse Oral LD 50 22 g/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 8 of 13
Version: 4.1

11. TOXICOLOGICAL INFORMATION

Polysorbate 80

Rat Oral LD50 25 g/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Hydroxypropyl methylcellulose

Rat Oral LD50 > 10,000 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg

Rat Subcutaneous LD50 50 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Exemestane

Eye Irritation Rabbit Minimal

Skin Irritation Rabbit Non-irritating

Skin Sensitization - M & K Guinea Pig Negative

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Exemestane

4 Week(s) Rat Oral 150 mg/kg/day NOEL None identified

4 Week(s) Rat Oral 1000 mg/kg/day LOEL Liver, Thymus, Spleen, Reproductive system

4 Week(s) Dog Oral 30 mg/kg/day LOEL Reproductive system

13 Week(s) Mouse Oral 30 mg/kg/day LOEL Reproductive system

26 Week(s) Rat Oral 30 mg/kg/day LOEL Female reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Exemestane

Reproductive & Fertility-Males Rat Oral 500 mg/kg/day LOEL Fertility

Fertility and Embryonic Development Rat Oral 20 mg/kg/day LOEL Fetotoxicity

Fertility and Embryonic Development Rat Oral 215 mg/kg/day LOEL Fertility, Fetotoxicity

Embryo / Fetal Development Rat Oral 10 mg/kg/day LOEL Developmental toxicity

Embryo / Fetal Development Rabbit Oral 30 mg/kg/day LOEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Exemestane

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 9 of 13
Version: 4.1

11. TOXICOLOGICAL INFORMATION

<i>In Vitro</i> Chromosome Aberration	Human Lymphocytes	Positive
<i>In Vivo</i> Chromosome Aberration	Mouse Bone Marrow	Negative
Unscheduled DNA Synthesis	Rat Hepatocyte	Negative
Mammalian Cell Mutagenicity	Hamster	Negative

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Exemestane

2 Year(s)	Rat	Oral	315 mg/kg/day	NOAEL	Not carcinogenic
2 Year(s)	Mouse	Oral	150 mg/kg/day	LOAEL	Tumors, Liver, Kidneys

Carcinogen Status: See below

Silica colloidal, Ph. Eur.

IARC: Group 3 (Not Classifiable)

Crospovidone

IARC: Group 3 (Not Classifiable)

Polyvinyl alcohol

IARC: Group 3 (Not Classifiable)

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater. Harmful effects to aquatic organisms could occur.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Exemestane

<i>Pseudokirchneriella subcapitata</i> (Green Alga)	OECD	EC50	72 Hours	7.1 mg/L
<i>Oncorhynchus mykiss</i> (Rainbow Trout)	OECD	LC50	96 Hours	2.8 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Exemestane

Nostoc sp. (Freshwater Cyanobacteria) TAD MIC 40 mg/L

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Exemestane

OECD Activated sludge Ultimate (CO₂ Evolution) 15.21% After 28 Day(s) Not Ready

Bio-accumulative Potential:

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 10 of 13
Version: 4.1

Partition Coefficient: (Method, pH, Endpoint, Value)

Exemestane

Measured 7 Log P 2.5

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Exemestane

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Silica colloidal, Ph. Eur.

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Crospovidone

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 11 of 13
Version: 4.1

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Hydroxypropyl methylcellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed
Magnesium stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
Mannitol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-711-8
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-674-9
Methylparaben	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7
Macrogol 6000	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Polysorbate 80	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Exemestane Tablets
 Revision date: 29-May-2018

Page 12 of 13
 Version: 4.1

15. REGULATORY INFORMATION

Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Polyvinyl alcohol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Sodium starch glycolate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9
Simethicone emulsion	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Titanium dioxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 9/2/2011 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Magnesium carbonate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

SAFETY DATA SHEET

Material Name: Exemestane Tablets
Revision date: 29-May-2018

Page 13 of 13
Version: 4.1

Reproductive toxicity-Cat.1B; H360FD - May damage fertility. May damage the unborn child.
Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 29-May-2018

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet